Performance evaluation of four type-specific commercial assays for detection of herpes simplex virus type 1 antibodies in a Middle East and North Africa population

Aldisi, Rana; Elsidiq, Malaz S.; Dargham, Soha R.; Sahara, Afifah; Al-Absi, Enas S.; Nofal, Mariam Y.; Mohammed, Layla; Abu‐Raddad, Laith J.; Nasrallah, Gheyath K.

doi:10.1016/j.jcv.2018.03.011

Cited by 12 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…58 Also, the assay used in HEV detection could affect the prevalence rate since there is a variation in the performance, sensitivity, and specificity between different serological assays. 59,60 Future studies should be done to estimate the actual prevalence of HEV in Egypt.…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes and Prevalence of Hepatitis E Virus (HEV) Among Non-A-C Hepatitis Patients in Egypt

Sayed¹,

El‐Mokhtar²,

Mahmoud³

et al. 2021

IDR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes and Prevalence of Hepatitis E Virus (HEV) Among Non-A-C Hepatitis Patients in Egypt

Sayed¹,

El‐Mokhtar²,

Mahmoud³

et al. 2021

IDR

View full text Add to dashboard Cite

“…Of note, different assays used different cut-off points. For example, for HerpeSelect® 1 ELISA, sera with optical density index values ≥ 1.10 were considered seropositive and <0.90 seronegative, with the rest deemed equivocal 38,39 . Meanwhile, for Euroimmun Anti-HSV-1 ELISA, sera with optical density index values ≥ 1.10 were considered seropositive and <0.80 seronegative, with the rest deemed equivocal 39,40 .…”

Section: Methodsmentioning

confidence: 99%

Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions

Chaabane

Harfouche

Chemaitelly

et al. 2019

Sci Rep

Self Cite

View full text Add to dashboard Cite

This study aimed at characterizing herpes simplex virus type 1 (HSV-1) epidemiology in the Middle East and North Africa (MENA). HSV-1 records were systematically reviewed. Findings were reported following the PRISMA guidelines. Random-effects meta-analyses were implemented to estimate pooled mean HSV-1 seroprevalence. Random-effects meta-regressions were conducted to identify predictors of higher seroprevalence. Thirty-nine overall seroprevalence measures yielding 85 stratified measures were identified and included in the analyses. Pooled mean seroprevalence was 65.2% (95% CI: 53.6–76.1%) in children, and 91.5% (95% CI: 89.4–93.5%) in adults. By age group, seroprevalence was lowest at 60.5% (95% CI: 48.1–72.3%) in <10 years old, followed by 85.6% (95% CI: 80.5–90.1%) in 10–19 years old, 90.7% (95% CI: 84.7–95.5%) in 20–29 years old, and 94.3% (95% CI: 89.5–97.9%) in ≥30 years old. Age was the strongest predictor of seroprevalence explaining 44.3% of the variation. Assay type, sex, population type, year of data collection, year of publication, sample size, and sampling method were not significantly associated with seroprevalence. The a priori considered factors explained 48.6% of the variation in seroprevalence. HSV-1 seroprevalence persists at high levels in MENA with most infections acquired in childhood. There is no evidence for declines in seroprevalence despite improving socio-economic conditions.

show abstract

“…Blood specimens were collected from 394 volunteering individuals between July 26 and September 9, 2020, as a sub-study of a nationwide survey [8] assessing SARS-CoV-2 seroprevalence (IgG antibodies) and current-infection prevalence (using polymerase chain reaction [PCR] testing) in the wider population of craft and manual workers who constitute 60% of the population of Qatar [11]. Informed by prior work [12, 13], a sample size of 400 was estimated to be sufficient to ensure narrow confidence intervals for the Cohen’s kappa statistic, but we were able to include and test only 394 specimens. The research work was approved by the ethics review boards at HMC, QU, and Weill Cornell Medicine-Qatar.…”

Section: Methodsmentioning

confidence: 99%

Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting

Nasrallah

Dargham

Shurrab

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundPerformance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 ever (past or current) infection in a population-based sample in a high exposure setting.MethodsPCR and serological testing was performed on 394 individuals.ResultsSARS-CoV-2-IgG seroprevalence was 42.9% (95% CI 38.1%-47.8%), 40.6% (95% CI 35.9%-45.5%), and 42.4% (95% CI 37.6%-47.3%) using the CL-900i, VidasIII, and Elecsys assays, respectively. Between the three assays, overall, positive, and negative percent agreements ranged between 93.2%-95.7%, 89.3%-92.8%, and 93.8%-97.8%, respectively; Cohen kappa statistic ranged from 0.86-0.91; and 35 specimens (8.9%) showed discordant results. Among all individuals, 12.5% (95% CI 9.6%-16.1%) had current infection, as assessed by PCR. Of these, only 34.7% (95% CI 22.9%-48.7%) were seropositive by at least one assay. A total of 216 individuals (54.8%; 95% CI 49.9%-59.7%) had evidence of ever infection using antibody testing and/or PCR during or prior to this study. Of these, only 78.2%, 74.1%, and 77.3% were seropositive in the CL-900i, VidasIII, and Elecsys assays, respectively.ConclusionsAll three assays had comparable performance and excellent agreement, but missed at least 20% of individuals with past or current infection. Commercial antibody assays can substantially underestimate ever infection, more so when infection rates are high.

show abstract

Performance evaluation of four type-specific commercial assays for detection of herpes simplex virus type 1 antibodies in a Middle East and North Africa population

Abstract: The assays showed excellent concordance with one another, and with a high kappa statistic. The ELISA kits demonstrated robust diagnostic performance compared to the IB/WB assays. These findings support the assays' utility in clinical diagnosis and research in MENA populations.

Cited by 12 publications

References 31 publications

Clinical Outcomes and Prevalence of Hepatitis E Virus (HEV) Among Non-A-C Hepatitis Patients in Egypt

Clinical Outcomes and Prevalence of Hepatitis E Virus (HEV) Among Non-A-C Hepatitis Patients in Egypt

Herpes simplex virus type 1 epidemiology in the Middle East and North Africa: systematic review, meta-analyses, and meta-regressions

Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting

Contact Info

Product

Resources

About